Mall of America

Axis Communications Opens Innovative Technology Center at Mall of America® Office Tower

Retrieved on: 
Thursday, December 8, 2022
Other Retail, Technology, Manufacturing, Security, Other Technology, Other Manufacturing, Retail, Other Defense, Defense, Audio, Video, Engineering, STE, Axis Communications, Office, VMS, Axis, Mall, Knowledge, Microsoft Office Live Meeting, Operation, AEC, Health, Minneapolis–Saint Paul, Multimedia, Education, Mall of America, Communication, Interior design, Telescopic sight

Axis Communications today unveils its newest Axis Experience Center (AEC) at The Offices @ MOA which adjoins the world-famous Mall of America in Bloomington, MNthe largest mall in the US.

Key Points: 
  • Axis Communications today unveils its newest Axis Experience Center (AEC) at The Offices @ MOA which adjoins the world-famous Mall of America in Bloomington, MNthe largest mall in the US.
  • View the full release here: https://www.businesswire.com/news/home/20221208005033/en/
    The Axis Experience Center in Minnesota is located at The Offices @ MOA which adjoins the world-famous Mall of America at 2131 Lindau Lane, STE 620, Bloomington, MN 55425.
  • It features a state-of-the-art Solutions Lab that showcases Axis Communications latest products and solutions for local partners and customers.
  • We are excited to welcome the Axis Experience Center as we mark their first location in the Upper Midwest.

Serum Albumin Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Health, Pharmaceutical, Molecule, Therapy, Research and development, R, Key, Product description, Research, ALB, Mall of America, Route of administration, History, Administration, News, Pharmaceutical industry, Serum albumin

The "Serum Albumin Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serum Albumin Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Serum Albumin (ALB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Serum Albumin (ALB) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Serum Albumin (ALB) targeted therapeutics development and features dormant and discontinued projects.

Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis

Retrieved on: 
Tuesday, November 22, 2022
Uveitis, DED, AAU, Severe cognitive impairment, Treatment, DME, Geographic atrophy, Inflammation, Antibody, Translational Vision Science & Technology, University, Glaucoma, ARVO, IOP, Risk, Physician, Diabetic retinopathy, Patient, Aqueous humour, Random phase approximation, AON, Disease, Swelling, Vision, Duane syndrome, NIH, Cataract, SUN, Mall of America, Pharmaceutical industry, AC, Ophthalmology, Pecten oculi

The study, Topical Ocular Anti-TNF Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study, is accessible on the National Institutes of Health (NIH) website here .

Key Points: 
  • The study, Topical Ocular Anti-TNF Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study, is accessible on the National Institutes of Health (NIH) website here .
  • Licaminlimab (OCS-02) was observed to be well tolerated, including no increase in intra-ocular pressure related to licaminlimab (OCS-02).
  • Licaminlimab (OCS-02) is an anti-TNF antibody product candidate based on an innovative antibody fragment technology allowing it to be administered topically.
  • Phase 2b clinical trials of licaminlimab (OCS-02) for the treatment of non-infectious anterior uveitis, as well as dry eye disease (DED), are currently being planned by Oculis.

NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

Retrieved on: 
Monday, November 14, 2022
Risk, MD Anderson Cancer Center, Medical Affairs Bureau, Index (publishing), AMF, III, Metastasis, Patient, Neoplasm, University, LA, Radiation, LAPC, Trial of the century, COVID-19, NBTXR3, Lung, MTD, Pancreatic cancer, Life, Cancer, RT, Annual report, HNSCC, Nanotechnology, DLT, Monroe Dunaway Anderson, Cetuximab, Safety, Nanoparticle, EIB, NANO, Central nervous system, MD, Mall of America, Survival, Pharmaceutical industry, Nanobiotix, Euronext

The phase 1 study (Study 2019-1001) is being conducted by The University of Texas MD Anderson Cancer Center (MD Anderson).

Key Points: 
  • The phase 1 study (Study 2019-1001) is being conducted by The University of Texas MD Anderson Cancer Center (MD Anderson).
  • The complete dose escalation part of the study recruited 11 patients, and all patients had unresectable disease at study entry.
  • A single intratumoral injection of NBTXR3 followed by 15 fractions of RT showed to be feasible and well-tolerated and the recommended phase 2 dose of NBTXR3 was established at 42% of gross tumor volume.
  • MD Anderson Study 2019-1001 is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D); and (ii) expansion at RP2D.

2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Pharmaceutical, Urination, Mall of America, Headache, Kidney disease, History, Polycystic kidney disease, Genetic, Blood, PKD, Cyst, R, Urine, ROA, Discovery, Genetic disorder, Diuretic, News, Human, Therapy, Research, Disorder, Pharmaceutical industry, Surveying, Marketing

Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure.

Key Points: 
  • Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure.
  • The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Health, Climate Change, Pharmaceutical, Oncology, A.I, FDA, IC50, Marketing, Permeability, Mouse, Brain, Clinical trial, Brain tumor, Probability, Poster, Johns Hopkins University, GBM, Kennedy Krieger Institute, Johns Hopkins, Machine learning, SOC, Patient, DNA, Pakistan Society of Neuro-Oncology, Cancer, Drug Quality and Security Act, CNS, Glioblastoma, ATRT, Spironolactone, Research, Security (finance), Food and Drug Administration Amendments Act of 2007, TMZ, IND, Society, Risk, Annual report, Pancreatic cancer, Therapy, Temozolomide, COVID-19, Judgement, DDR, Mall of America, ERCC3, SNO, Orphan, Food, ADC, Pharmaceutical industry, Lantern

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")
  • In our SNO poster, we demonstrated the exquisite in vitro/in vivo efficacy of LP-184 towards GBM as a single agent or in combination with spironolactone.
  • Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR A.I.
  • Lantern is currently developing four drug candidates and an ADC program across eleven disclosed tumor targets, including two phase 2 programs.

Nintendo News: Nintendo Delivers Holiday Cheer to Malls Across the Nation

Retrieved on: 
Thursday, November 10, 2022
Software, Internet, Hardware, Online, Consumer Electronics, Technology, Electronic Games, Entertainment, Online, Nintendo Account, Splatoon, Nintendo Switch, Internet access, Scarlet, Minecraft, Mall, DLC, Mall of America, Nintendo Switch Online, Video game console, Online shopping, Nintendo, Hope

The Wishlist Wonderland with Nintendo Switch stop at Mall of America in Bloomington, Minnesota, will start on Nov. 19.

Key Points: 
  • The Wishlist Wonderland with Nintendo Switch stop at Mall of America in Bloomington, Minnesota, will start on Nov. 19.
  • Wishlist Wonderland with Nintendo Switch is open to everyone no signup needed and encourages attendees to personalize their own Nintendo Switch holiday wishlist with the latest systems and games.
  • While visiting the Wishlist Wonderland with Nintendo Switch experience, consumers will be able to demo select Nintendo Switch games in TV mode and handheld mode.
  • Nintendo Switch Online membership (sold separately) and Nintendo Account required for online features.

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients

Retrieved on: 
Tuesday, October 25, 2022
RNA transfection, Therapy, Achievement, IND, Korean Ministry of Culture, U.S. FDA, Patient, Hepatocellular carcinoma, RNA, HCC, Technology, Cancer, Mutation, Retinitis, Alzheimer's disease, CEO, Safety, Toxic Small RNA, Clinical trial, Mall of America, DNA, Glioblastoma, FDA, Retinitis pigmentosa, Reverse transcriptase, Duke University, Pharmaceutical industry, Vaccine, Food

Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.

Key Points: 
  • Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • Also under development are ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients

Retrieved on: 
Tuesday, October 25, 2022
RNA transfection, Therapy, Achievement, IND, Korean Ministry of Culture, U.S. FDA, Patient, Hepatocellular carcinoma, RNA, HCC, Technology, Cancer, Mutation, Retinitis, Alzheimer's disease, CEO, Safety, Toxic Small RNA, Clinical trial, Mall of America, DNA, Glioblastoma, FDA, Retinitis pigmentosa, Reverse transcriptase, Duke University, Pharmaceutical industry, Vaccine, Food

Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.

Key Points: 
  • Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • Also under development are ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).

TruChoice Hosts Inaugural Discover Conference

Retrieved on: 
Friday, October 21, 2022
LLC, LinkedIn, TruChoice Federal Credit Union, Insurance, GLOBE, Mall, Industry, Twitter, LIFE, JW Marriott Hotels, SEA, Mall of America, Public relations, Facebook

MINNEAPOLIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- TruChoice Financial Group, LLC (TruChoice), one of the largest distributors of insurance products in the financial services industry, held its first annual Discover conference Oct. 12-14 at the JW Marriott Minneapolis Mall of America in Bloomington, Minnesota.

Key Points: 
  • MINNEAPOLIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- TruChoice Financial Group, LLC (TruChoice), one of the largest distributors of insurance products in the financial services industry, held its first annual Discover conference Oct. 12-14 at the JW Marriott Minneapolis Mall of America in Bloomington, Minnesota.
  • Discover '22 was kicked off by industry legend Tom Hegna, who also took the time to mingle with attendees at the opening night reception.
  • The feedback we've received so far is overwhelmingly positive, and we're excited to start looking ahead to Discover '23 next year."
  • For more information about TruChoice events, or to learn more about TruChoice, visit www.TruChoiceFinancial.com , or call 800.237.0263.